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Cystic fibrosis transmembrane conductance regulator mutations
that disrupt nucleotide binding.
J Logan, … , W J Cook, E J Sorscher
J Clin Invest. 1994;94(1):228-236. https://doi.org/10.1172/JCI117311.
Increasing evidence suggests heterogeneity in the molecular pathogenesis of cystic fibrosis (CF). Mutations such as
deletion of phenylalanine at position 508 (delta F508) within the cystic fibrosis transmembrane conductance regulator
(CFTR), for example, appear to cause disease by abrogating normal biosynthetic processing, a mechanism which results
in retention and degradation of the mutant protein within the endoplasmic reticulum. Other mutations, such as the
relatively common glycine-->aspartic acid replacement at CFTR position 551 (G551D) appear to be normally processed,
and therefore must cause disease through some other mechanism. Because delta F508 and G551D both occur within a
predicted nucleotide binding domain (NBD) of the CFTR, we tested the influence of these mutations on nucleotide binding
by the protein. We found that G551D and the corresponding mutation in the CFTR second nucleotide binding domain,
G1349D, led to decreased nucleotide binding by CFTR NBDs, while the delta F508 mutation did not alter nucleotide
binding. These results implicate defective ATP binding as contributing to the pathogenic mechanism of a relatively
common mutation leading to CF, and suggest that structural integrity of a highly conserved region present in over 30
prokaryotic and eukaryotic nucleotide binding domains may be critical for normal nucleotide binding.
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Abstract
Increasing evidence suggests heterogeneity in the molecular
pathogenesis of cystic fibrosis (CF). Mutations such as dele-
tion of phenylalanine at position 508 (AF508) within the
cystic fibrosis transmembrane conductance regulator
(CFTR), for example, appear to cause disease by abrogating
normal biosynthetic processing, a mechanism which results
in retention and degradation of the mutant protein within
the endoplasmic reticulum. Other mutations, such as the
relatively common glycine -, aspartic acid replacement at
CFTR position 551 (G551D) appear to be normally pro-
cessed, and therefore must cause disease through some other
mechanism. Because AF508 and G551D both occur within
a predicted nucleotide binding domain (NBD) of the CFTR,
we tested the influence of these mutations on nucleotide
binding by the protein. Wefound that G551Dand the corre-
sponding mutation in the CFTRsecond nucleotide binding
domain, G1349D, led to decreased nucleotide binding by
CFTRNBDs, while the AF508 mutation did not alter nucle-
otide binding. These results implicate defective ATPbinding
as contributing to the pathogenic mechanism of a relatively
commonmutation leading to CF, and suggest that structural
integrity of a highly conserved region present in over 30
prokaryotic and eukaryotic nucleotide binding domains
may be critical for normal nucleotide binding. (J. Clin. In-
vest. 1994. 94:228-236.) Key words: cystic fibrosis * genetics
* pathogenesis * ATP * structure
Introduction
Many of the mutations which cause clinical cystic fibrosis (CF)l
occur within the two nucleotide binding domains of the cystic
fibrosis transmembrane conductance regulator (CFTR) (1-3).
While the precise role of the nucleotide binding domains
(NBDs) in CFTR function is still unknown, previous studies
Address correspondence to E. J. Sorscher, Department of Physiology
and Biophysics, University of Alabama at Birmingham, UAB Station,
Birmingham, AL 35294-0005.
Received for publication 16 June 1993 and in revised form 21
December 1993.
1. Abbreviations used in this paper: ABC, ATP binding cassette; CF,
cystic fibrosis; CFTR, CF transmembrane regulator; GST, glutathione-
s-transferase; NBD, nucleotide binding domain.
have shown that the anion channel function of CFTR is depen-
dent upon the presence of ATP or other nucleotides (4-8).
Studies in our laboratory (9) as well as by others (10, 11 ) have
suggested that AF508, the most common mutation associated
with clinical CF, is not associated with disrupted nucleotide
binding by folded CFJlR polypeptides. Phenylalanine 508 is not
highly conserved among the NBDsof more than 30 prokaryotic
and eukaryotic members of the ATP binding cassette (ABC)
gene family which includes CFTR(1, 12, 13); this observation
has suggested that the F508 residue might not directly contribute
to ATPbinding by CFTR. In addition, increasing evidence sug-
gests that CFTRpossessing the AF508 mutation is improperly
processed within epithelial cells, and that disease results because
the mutant protein fails to insert properly in the apical cell
membrane (14-17). Such a pathogenic mechanism is not likely
to be dependent upon ATP binding by the NBD.
The second most common mutation leading to clinical
cystic fibrosis is a glycine to aspartic acid replacement within
NBD-1 at CFTRposition 551 (G551D) (2, 18, 19). Because
(a) both G551D and the corresponding mutation in NBD-2,
G1349D, cause clinical CF; (b) both mutations involve a
glycine residue which is invariant in alignments of > 30 nu-
cleotide binding domains from the ATPbinding cassette gene
family (1, 12, 13); (c) chloride channel studies from heterol-
ogous eukaryotic cells expressing recombinant CFTR have
raised the possibility of a defective response to ATPby CFTR
with these mutations (5); and (d) both G551D and G1349D
appear to be normally processed to the cell membrane, (5, 14,
15), we tested the influence of these mutations on nucleotide
binding by CFTRNBDs. Wefound that G551D and G1349D,
but not AF508, significantly decreased nucleotide binding
by recombinant NBDs. These results directly demonstrate
abnormal nucleotide binding as the result of CFTRmutations,
and may have important implications concerning the general
structure of nucleotide binding domains within the ABCgene
family.
Methods
Recombinant synthesis and purification of CFTR nucleotide binding
domains. A series of polymerase chain reaction (PCR) primers defining
CFTRNBD-l (AA426 to 588, 5 'GCGCGAATTCATGACAGCCTC-
TTCTTCAG3' and 5 'GCCATCAGTTTACAGACACAGAATTCAAA
3') or NBD-2 (amino acids 1219 to 1387, 5 'GCGCGAATTCAATAC-
ACAGAAGGTGGAAATGCC3'and 5 'GTGCAATCAGCAAATGC-
TTGTTTTAGAATTCTTC3')were used to amplify the respective wild-
type and mutant NBDs from CFTRcDNA plasmid templates obtained
from the American Tissue Culture Collection (Rockville, MD) (wild
type: ATCCno. T16-1 and AF508: ATCCno. Cl -1/ 5) or as a generous
gift from Alan Smith and Richard Gregory (Genzyme Corp., Cambridge,
MA) (full length CFTRcDNAs containing G551D or G1349D) (4, 5,
15). PCRconditions were 1 min x 94°C denaturation, 2 min X 50°C
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Figure 1. Synthesis and purification of recombinant CFTRNBD-l and NBD-2. (A) CFTRNBDs 1 and 2 were synthesized as fusion proteins with
GSTand induced using isopropyl 13-D-thiogalactopyranoside (Sigma Chemical Co.) (IPTG), according to a previously described protocol (9).
Lanes 2 and 3 show total E. coli cell lysate prior to and after IPTG induction, respectively (upper arrow, GST/wild type NBD-l fusion protein).
Lane 4, following dialysis into a protease cleavage buffer, human thrombin was used to cleave the fusion protein into its two constituents; a 28-
kD glutathione-s-transferase fragment (middle arrow) and the 21 -kD wild-type NBD-1 (lowest arrow). Lane 1 contains molecular mass standards.
(B) Cleaved material such as that shown in panel A., lane 4 was loaded on a preparative electrophoresis cell (Bio Rad). Proteins were separated
on the basis of molecular mass and collected in 5-ml fractions as they eluted from the bottom of the gel. Lanes B-J are 20-gl samples from every
fifth fraction. The purified NBD-l (21 kD) is seen in lanes D and E. Molecular mass standards are shown in lane A. (C) Using the same approach,
a series of wild-type and mutant NBDs were purified. Lane A, wild-type NBD-1; lane B, AF508 NBD-1; lane C, G551D NBD-1; lane D, wild-
type NBD-2; lane E, G1349D NBD-2; lane F, molecular mass standards. Gels in A-C contain 12% acrylamide. GST/NBDfusion proteins run
aberrantly on 12% SDS-PAGE(- 43 kD). This has been noted for all five independently cloned NBDpolypeptides used in this study, as well as
for four additional full length NBDmutants (not shown).
annealing, and 3 min x 72°C elongation. Primers were chosen to create
EcoRI sites at the ends of PCRproducts to allow cloning into the EcoRI
site of pGEX2T (Pharmacia Fine Chemicals, Piscataway, NJ) in frame
with glutathione-s-transferase (GST) and immediately 3' to an engi-
neered thrombin cleavage site (9). All PCRproducts obtained by this
method were of the predicted size (524-bp NBD-1, 545-bp NBD-2). In
addition, identity of correct recombinants were verified by (a) restriction
mapping using 10-12 digests per recombinant construct; (b) re-ampli-
fication of the full length NBDinsert using the recombinant plasmid as
template; (c) recombinant plasmid-directed synthesis of fusion protein
and specific cleavage by human thrombin into the two predicted frag-
ments; and (d) amino-terminal sequencing and compositional analysis
(13 amino-terminal residues of NBD-1 and 12 amino-terminal residues
of NBD-2, as well as > 30 internal residues obtained during peptide
mapping matched the predicted sequence of the recombinant proteins).
Recombinant fusion protein was collected and partially purified as an
inclusion body preparation as described previously (9). After thrombin
treatment (in a protease cleavage buffer containing 50 mMTris HC1,
150 mMNaCl, 2.5 mMCaCl2, pH 7.4, and 20 U human thrombin
(Sigma Chemical Co., St. Louis, MO)/ 10 mgrecombinant protein) - 3
mg of the partially purified, cleaved preparation (i.e., containing NBD,
GST, some uncleaved fusion protein and minor bacterial contaminants)
was applied to the top of a preparative acrylamide gel (Bio Rad Labora-
tories) and the NBDpurified using electrophoresis through 12% acryl-
amide as in Fig. 1 B. The observation that the polyacrylamide gel
electrophoresis based protein purification step used here required solubi-
lization in 0.8% SDS is consistent with a recent report that solubilization
of recombinant full length CFTR was refractory to a large series of
detergents, but ultimately could be solubilized in 2% SDS while still
permitting efficient (20-40%) refolding of the protein into a native
form capable of supporting CFTRanion channel activity in the planar
lipid bilayer (6).
Trinitrophenyl ATP binding by NBDs. 250 .g per ml purified NBD-
1 (- 10 M1M) in 10 mMTris, pH 7.4, was incubated at 40C with
increasing concentrations of trinitrophenyl ATP (TNP-ATP; Molecular
Probes, Inc., Eugene, OR). TNP-ATP demonstrates fluorescence en-
hancement when present in a nucleotide binding pocket (10, 11). Ade-
nine nucleotide fluorescence was measured at each data point for 1 s in
a 1-ml quartz cuvette using a Perkin Elmer LS-50 spectrofluorometer
(Perkin-Elmer Corp., Norwalk, CT) with excitation 408 nM and emis-
sion 538 nM. Fluorescence enhancement was determined at each data
point by measuring (a) the fluorescent signal of buffer plus TNP-ATP
at each concentration studied; (b) the fluorescence of protein in buffer
alone; and (c) the fluorescent signal of protein + TNP-ATP at each
concentration and using the calculation: fluorescence enhancement
= (fluorescence signal of protein + TNP-ATP) - (fluorescence of TNP-
ATPalone + fluorescence of protein alone). Because preliminary exper-
iments indicated that binding of TNP-ATP to the NBD-1 is not depen-
dent upon divalent cations, Mg2` was not added to the titration solutions.
y32p-2-azido ATP labeling of NBDs. 2-azido ATP was synthesized
from 2 azido AMP(20) by the method of Michelson as modified by
Salvucci et al. (21). [y-32p]2-azido ATP (sp. act. 5-35 mCi/,.mol)
was then prepared and purified as described previously (22). The purity
[y-32P]2-azido ATP was determined by TLC analysis.
Photoaffinity labeling was conducted at 4°C in 50-IA reactions con-
taining 4 ,ug purified recombinant NBD, 10 mMtris, 10 mMMgCl2,
pH 7.1 (without ATP present) and the indicated amount of photoprobe.
Reactions were initiated by the addition of photoprobe. After a 30-s
incubation, the reactions were photolyzed for 1 min with a hand-held
254-nm UV lamp (I = 3,100 HIW/cm2). After photolysis, samples were
precipitated with an equal volume of 7% perchloric acid and resolubi-
lized in a buffer containing 10%SDS, 3.6 Murea, 162 mMdithiothreitol,
m-Cresol purple as a tracking dye, and 20 mMTris-HCl, pH. 8.0.
Samples were then subjected to electrophoresis by an 8-12% SDS-
PAGEseparating gel with a 4% stacking gel according to the method
of Laemmli (23). Gels were then stained, fixed, and labeling quantified
on an AMBIS 4000 Imaging System (Ambis, Inc., San Diego, CA).
Results
Weused prokaryotic over-expression to generate quantities of
CFTlR NBDs sufficient for binding and structural studies (Fig.
1). Because recombinant proteins synthesized in bacteria (as
well as in eukaryotic cells) commonly require refolding proto-
cols to establish binding or other activity, care was taken to
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obtain a refolding sequence relevant to the native CFTRstruc-
ture and function. First, we have previously shown that recombi-
nant wild-type and AF508 CFTRNBD-1 derived from bacteria
bind ATP affinity agarose as well as 32p-8-azido ATP (9). The
data presented below indicates that two additional ATPanalogs,
trinitrophenyl ATP and 32p-2-azido ATP, also bind the recom-
binant NBD. All four ligands can be displaced by Na2 ATP
with half maximal displacement occurring at - 5 mMATP. (9,
E. J. Sorscher and J. Logan, unpublished observations). Second,
the proteins generated for these studies display substantial sec-
ondary structural content (- 70% ,3 sheet, 10% a helix) when
studied by circular dichroism, a result in agreement with a high
,/ sheet content reported for a synthetic peptide corresponding
to a 67 amino acid segment of the NBD-1 (10). Third, although
in vitro studies of recombinant CFTRusing cell free membrane
patches have demonstrated half maximal ATP stimulation at
- 270 jIM (4), the ATP binding affinity constants which we
have observed for NBD-1 are very similar to those reported for
CFTRCl - conductance reported in both native, perfused human
sweat ducts and in a non-recombinant human cell line express-
ing high levels of CFTR(T84) (7, 24; see also 8). Half maximal
CFTR activity in both systems was reported at 3-5 mM, a
finding which suggested that cellular ATP levels may represent
an important regulatory constraint on CFTRanion channel ac-
tivity. These observations indicate that the nucleotide binding
domains used in our studies possess substantial structure after
refolding and bind ATP with an affinity very similar to that
observed in macroscopic measurements of full length CFTR
Cl- conductance.
Weused two independent assays of nucleotide binding to
test the significance of the AF508 and G551D mutations (Fig.
2). NBD-1 containing the AF508 mutation demonstrated very
similar binding to the wild type NBD-1 as measured using either
TNP-ATP or 32p-2-azido ATP. This result is consistent with
previous studies in our laboratory using other measurements of
nucleotide affinity (9), as well as with conclusions reached
using fully folded synthetic peptides corresponding to portions
of the CFTRNBD-1 with and without F508 (11), and with a
computer-based model of the NBDderived from a secondary
structural alignment containing the known two- and three-di-
mensional structure of adenylate kinase (12, see below). In
contrast, as shown in Fig. 2 A, the G551D mutation inhibited
-0.8 -0.6 -0.4 -0.2 0.0 0.2 0.4 0.6
Concentration
Figure 2. (A) TNP-ATP binding by NBD-l. 250 jg/ml purified NBD-
1 in 10 mMTris, pH 7.4, was incubated at 4°C with increasing concen-
trations of trinitrophenyl ATP. Eadie Hofstee transformation of the
above data indicated an apparent half maximal binding at 3.1, 3.5,
and 2.9 MMfor wild type, AF508, and G551D, respectively; maximal
binding values were 0.92, 1.05, and 0.27 relative fluorescence units
for the three respective proteins. Binding of TNP-ATP by the wild type
NBD-l could be inhibited in the presence of 5 mMMg2 ATP (50%
inhibition at 5 mMMg2 ATP). TNP-ATP binding was completely ab-
sent in the presence of denaturing concentrations of urea (4 M), indicat-
ing the importance of proper folding of the recombinant NBDfor nucleo-
tide binding (not shown). n = 7 for wild type and G551D, n = 3 for
AF508. Error bars = SEM. (B) 32p-2 azido ATP labeling of NBD-1.
32p-2-azido ATP at the concentrations shown was incubated with NBD-
1 (4 Mg) for 30 s followed by 1 min of UV photolysis to covalently
label the recombinant proteins within the nucleotide binding site. The
gels were stained, fixed, and the labeling quantified on an Ambis 4000
Imaging System (Ambis, Inc.). In C, a Lineweaver-Burk plot of the
data is shown; half-maximal labeling was obtained at 1.3 MMfor the
wild-type NBD-1, 2.1 MMfor the /F508 NBD-1, and at 7.5 MMfor
NBD-1 containing the G551D mutation. To obtain maximal photolabel-
ing, 32p-2 azido ATP photolysis shown in B and C was performed in
the absence of free ATP.



















TNP-ATP fluorescence enhancement by the recombinant do-
main.
The half maximal TNP-ATP binding values observed for
wild type, AF508, and GS5lD were 3.1, 3.5, and 2.9 MM,
respectively, whereas the maximal binding occurred at 0.92,
1.05, and 0.27 relative fluorescent units. Weestimated a 5-mM
half-maximal ATPbinding based on ATPdisplacement of TNP-
ATPand 32p-2 azido ATP from the CFTRNBD- 1. In the NBD,
therefore, as in many nucleotide binding proteins, TNP-ATP
exhibits several orders of magnitude greater binding affinity
than does ATP. This may be due in part to the hydrophobic
phenyl group present in TNP-ATP and the hydrophobic nature
of many nucleotide binding sites. For example, in the gastric
H', K+-ATPase, the apparent KD for TNP-ATP binding was
< 25 nM, whereas the apparent half maximal binding by ATP
was 86 tM (25). In the Na/K ATPase purified from eel elec-
troplax, the KD for TNP-ATP was up to 580 times greater than
the KD for ATP, depending on the ionic conditions used (26).
Nucleotide binding by a peptide fragment of DNApolymerase
I also was substantially tighter for TNP-nucleotides (kD = 0.5-
1.5 MM) than for the corresponding nucleotides without phenyl
group attached (kD = 230-2,100 MM) (27).
Our estimated binding affinity for ATP agrees closely with
our previously reported estimates of ATP affinity for the NBD
(9), with macroscipic measurements of the ATP dependence
of CFTR Cl channel activity using two independent systems
(7, 24) and reasonably well with displacement of TNP-ATP
from a maltose binding protein/NBD-l fusion protein (28),
and with displacement of 32p-2 azido ATP from the full length
CFTR (29) (half-maximal displacement at 1 mM). How-
ever, while our results clearly indicate diminished nucleotide
binding mediated by the GSSlD mutation, the micromolar half
maximal binding constants using TNP-ATP which we observed
are not likely to predict the dependence of CFTRCl- channel
activity on ATPor other nonderivitized nucleotide triphosphates
(KD values for ATP dependence of CFTR chloride channel
have ranged between - 25 ,uM and 5 mM, depending on the
particular CFTR Cl- channel preparation used) (4, 5, 7,
24, 30).
The binding signal obtained with TNP-ATP reflects both
the instantaneous number of nucleotide binding sites occupied
by the ligand and the local environment within each site (which
in turn is reflected in the magnitude of fluorescence enhance-
ment). Because the binding environments within the nucleotide
pockets of the wild type, AFS08 and GSSlD NBD-l polypep-
tides may not be identical, the quantum of fluorescence enhance-
ment observed for each molecule of TNP-ATP which binds to
an NBDmolecule cannot be assumed to be the same for the
three recombinant NBD-1 proteins. However, even if the fluo-
rescent (quantum) yield for each binding event is different, if
the same number of binding sites exist in solution, the ligand
(TNP-ATP) concentration observed at saturation should not
vary between the three NBD-1 polypeptides. This is not the
case in our experiments (Fig. 2 A), where GSSlD saturates at
8-10 MmTNP-ATP, and saturation for the wild-type and the
AFS08 NBD occurred at significantly higher concentrations.
This results suggests that in addition to physically disrupting
the nucleotide binding pocket within the nucleotide binding site
(see Discussion), the G -- D replacement at position 551 might
also destabilize overall protein folding in such a way as to create
an equilibrium between NBDfolded and unfolded forms. The
result would be an apparent decrease in measurable binding
sites within the NBDpreparation and would explain the lower
ligand concentration at saturation for GSS1Ddescribed in Fig.
2 A. Ultraviolet spectral analysis of the structures of wild-type
and mutant NBDs in the presence and absence of nucleotides,
and in the presence of denaturants such as urea (9, 11 ) are in
progress to evaluate effects on protein folding stability mediated
by GSSlD.
To confirm that less nucleotide was actually bound to CFTR
polypeptides containing the GSSlD mutation, we performed an
additional series of experiments using an independent nucleo-
tide binding assay. As shown in Fig. 2, B and C, at concentra-
tions below saturation, 32p-2-azido ATP labeling is diminished
in the GSS1Dmutant as compared with wild type (half-maximal
photoinsertion was [in 1LM] 1.3 [wt]; 2.1 [AF508]; and 7.5
[GSS1D]. Because the two assays used in this study measure
complementary features of nucleotide binding environment and
ligand occupancy, taken together these results indicate defective
nucleotide binding mediated by the GSSlD mutation. While
the fluorescence enhancement observed for TNP-ATP binding
depends primarily upon the integrity and local environment of
a nucleotide binding pocket, 32p-2 azido ATP labeling not only
requires an adequate binding site, but also requires properly
oriented residues within the binding site which are accessible
for covalent photolabeling. In our experiments, the functional
defect caused by GSS1Dled to an apparent decreased maximal
binding by TNP-ATP (Fig. 2 A), and a diminished half maximal
binding in experiments using the 32p-2 azido ATP (Fig. 2 B).
Such an observation could be explained by a change in nucleo-
tide binding pocket hydrophobicity (causing a decreased fluo-
rescence signal from TNP-ATP even at maximal occupancy)
together with loss of one of a small number of sites normally
available for covalent photolabeling by 32p-2-azido ATP (an
abnormality with might be overcome at increasing concentra-
tions of photoaffinity ligand).
Although the glycine corresponding to G551 is invariant
among more than 30 ABCproteins (and an even larger numbers
of NBDs, since each ABC protein possesses 2 NBDs), the
functional significance of this glycine residue and the immedi-
ately adjacent, highly conserved residues found within all mem-
bers of the gene family is not known (Other members of the
gene family, for example, include the human multidrug resis-
tance gene (MDR), the chloroquine resistance gene product of
P. malaria, and the recently described human adrenoleukodys-
trophy gene [1, 12, 13, 31-34]). An LSGGQQXQRmotif is
highly conserved across the ABCgene family (glycine corre-
sponding to G551 underlined) (1, 12, 13), but is not present
in other nucleotide binding proteins such as adenylate kinase,
for example, or included within the so-called Walker A or
Walker B sequences characterizing a broad range of non-ABC
family, ATP-binding proteins (35, 36). It has been proposed
that in the histidine permease of S. typhimurium (an ABCpro-
tein), the residues near the LSG(JQXQR motif could serve
as a "linker peptide" which conveys conformational changes
between segments of the domain (37).
To further test our hypothesis that this conserved region
functions in nucleotide binding, we generated additional recom-
binant proteins corresponding to the wild-type CFTR NBD-2
and to NBD-2 containing a G1349D mutation (i.e., a mutation
in NBD-2 which causes clinical CF and occurs at the glycine
residue in NBD-2 which aligns with G551 in NBD-1). As
shown in Fig. 3, G1349D disrupts binding both of TNP-ATP
and 32p-2-azido ATP. Maximal binding values observed with
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Figure 3. Binding of nucleotide by CFTRNBD-2. A and B show TNP-ATP binding and 32p-2 azido ATP labeling of the wild-type and G1349D
NBD-2, respectively. Experiments were performed as in Fig. 2. Maximal binding of TNP-ATP to wild-type NBD-2 was 2.5 X greater than that
observed for the G1349D mutant. (Using algebraic transformation as described in the previous figure, for wt NBD-2, maximal binding = 8.9
fluorescence units; half maximal binding = 3.8 uMTNP-ATP; for G1349D, maximal binding = 3.5 fluorescence units, half maximal at 5.3 ILM
TNP-ATP). As shown in B, inclusion of G1349D within NBD-2 blocked azido nucleotide labeling of the protein. The magnitude of 32p-2 azido
ATP labeling is highly dependent upon the specific activity of the photoaffinity ligand used. The specific activity of 32p-2 azido ATP used in Fig.
3 B was 10-fold higher than that used in Fig. 2 B. Whenwild-type NBD-1 and NBD-2 were directly compared using photolabeling under identical
conditions (and using the same lot of 32p-2 azido ATP), a - 10-fold enhancement of maximal photolabeling was observed in NBD-2 compared
with NBD-1 (data not shown).
TNP-ATP were 8.9 fluorescence units (wild-type NBD-2) and
3.5 fluorescence units (G1349D NBD-2); half-maximal binding
was observed at 3.8 and 5.3 gcm TNP-ATP for the wt NBD-2 and
G1349D mutants, respectively. Half-maximal photoinsertion of
the wild type NBD-2 with 32p-2 azido ATP was observed at a
ligand concentration of - 13 um, whereas photolabeling was
substantially less for the G1349D compared with the wild-type
NBD-2 at every ligand concentration studied. These findings
have significance, since they suggest a general function of the
conserved glycine and surrounding residues may be in nucleo-
tide binding. The results are consistent both with previous obser-
vations indicating an abnormal ATP dependence in CFTRcon-
taining mutations in this glycine residue (5) and with the ob-
served loss of function of other ABC proteins containing
comparable mutations (38). However, experiments measuring
CFTRor other ABCprotein function could not distinguish be-
tween disrupted ATP binding, hydrolysis, or utilization of nu-
cleotide as the mechanism of observed abnormalities in func-
tion. Our data support the notion that in addition to abnormal
biosynthetic processing, cystic fibrosis may result from defects
in nucleotide binding by the CFTlR. It is likely that an additional
mechanism (i.e., absent CFTRpolypeptide due to the presence
of premature stop codons within certain mutant CFTRalleles)
may also account for the defect in some cases (18, 39).
Discussion
To test the influence of CF mutations on nucleotide binding,
we constructed and purified the CFTR domains which have
been implicated as both necessary and sufficient for nucleotide
interactions with CFTR (1-5, 9-13). The highly conserved,
functionally independent and even interchangeable nature of
CFTRand other nucleotide binding domains (which span - 200
amino acids and share 30% amino acid identity throughout the
ABCgene family) suggests that one approach to understanding
the molecular pathogenesis of CFTRmutations might focus on
the domains themselves, as opposed to any particular ATPbind-
ing cassette protein context. For example, the NBDsin the LIV-
I neutral branched chain amino acid transport system of E. coli
and the histidine permease of S. typhimurium are found on genes
separate from the remainder of the transport complex (and are
therefore synthesized separately), but assemble with the re-
mainder of the ABC complex at the cell membrane. When
CFTR NBDmutations were placed at corresponding residues
within these bacterial NBDs, (or within the NBDs of the yeast
mating factor transporter, STE 6), certain of these mutations
had functional effects consistent with those observed in CFTR
(although others did not. See refs. 37, 38, 40). Furthermore, in
ABCproteins containing both NBDswithin a single polypeptide
chain, the two NBDs can be separated and still maintain func-
tion. For example, when the STE 6 cDNA, which codes for
both NBDs of the protein, was severed into two halves, (each
of which contained one of the NBDs), coexpression of the two
STE 6 truncations led to functional reconstitution of STE 6
mediated a-factor transport (40).
NBDsare also interchangeable among members of the ABC
protein family. The NBD-1 of CFTR, for example, can be
grafted into STE 6 in place of the STE 6 NBD-1 to allow

















functional transport of mating factor. Importantly, NBD-1 muta-
tions known to disrupt CFTR function also led to disrupted
mating factor transport by the chimeric STE 6/CF]R protein
(41). Finally, although data concerning a requirement for ATP
hydrolysis in CF`R activity is not yet conclusive, in some
members of the ATP binding cassette gene family known to
hydrolyze ATP, isolated NBDs are sufficient to mediate this
hydrolysis (12, 42, 43). Taken together, these findings demon-
strate that the NBDs within the ATP binding cassette family
are functionally independent, self-contained "cassettes" and
emphasize (a) that characterization of the nucleotide binding
domains, themselves, (independent of the transmembrane, regu-
latory and other regions within ATP binding cassette proteins)
can offer substantial insight into the mechanism of action within
this family of gene products, and (b) the relevance of normal
and abnormal function of the domains to the activity of the full
length ABCproteins. Indeed, in a similar approach to that ap-
plied in the current study, binding and structural studies of
synthetic peptides corresponding to portions of the CFTRNBD-
1 (10, 11), as well as computer-assisted models of isolated
nucleotide binding domains based on secondary structural align-
ments with the known crystal structures of adenylate kinase,
p21 ras, and the elongation factor Tu, have previously been
used to predict the significance of clinically important mutations
on CFTRnucleotide binding and function (see below, 12, 13).
NBDswithin the ABCfamily very likely subserve similar func-
tions, so that conclusions concerning the CFTRNBD-1 could
be applicable to CFTRNBD-2 and to NBDs of other members
of the gene family as well.
The maximal binding of TNP-ATP by wild type and AF508
NBD-l was 3-4-fold greater than that observed for the G551D
mutant. Defective maximal binding capacity of a similar magni-
tude has been proposed to account for some forms of familial
hypercholesterolemia (in which ligand binding by mutant LDL
receptor is decreased by fourfold) (44), for oxygen affinity
mutants in clinical hemoglobinopathies (45), as well as in the
twofold difference in binding or enzymatic function which ac-
counts for enzymatic defects of many congenital diseases (e.g.,
those inherited in an autosomal dominant fashion) (46). In
addition, since in most cases the G -+ D mutant allele causes
disease in conjunction with a AF508 allele, nucleotide binding
in a compound heterozygote (which may already be 50% de-
creased due to aberrant processing of the AF508 gene product)
might represent only a residual of 15-20% of that seen in a
wild-type cell.
Although the anion channel activity of wild-type and mutant
CFTRpolypeptides has become the most useful endpoint defin-
ing normal CFTR function, mutations which cause clinical CF
in many cases cause only small alterations in channel activity
in vitro. For example, in a series of four NBD-1 and NBD-2
mutations which cause disease (including G1349D and
GSS1S), although 4-8-fold differences in open probability
were observed in vitro when compared with wild type, no abnor-
malities in maximal single channel currents could be docu-
mented (although small differences in the dependence of current
on ATP were observed for the mutants) (5). In vivo, potential
difference measurements in respiratory epithelia of CF patients
differ by less than threefold compared with normal controls
(47, 48). This data further supports the notion that even subtle
changes in normal CFTRfunction may have important physio-
logic consequences. Finally, measurements of CFTRactivity in
intact human tissues and cell monolayers have indicated that
half maximal CFTR activation requires maximal cellular ATP
levels (- 5 mM), and that CFTR activity may be coupled to
physiologic nucleotide levels within the cell (7, 24). The de-
crease in binding of ATP analogs demonstrated here has sig-
nificance, therefore, since a similar defect in nucleotide binding
in vivo could result in mutant CFTRwhich would be activated
only at nucleotide levels which are not present within the cell.
Our studies using recombinant CFTRNBDs provide a test
of recent predictions concerning the function and structure of
NBDs within the ABCgene family. For example, based upon
Michaels-Menten analyses of the ATP dependence of CFTR
anion channel open probability, it has been proposed both that
the full length CFTRcontains only one functional ATPbinding
site (30), and that two active nucleotide binding sites are pres-
ent within the full length molecule (5). Our results are the first
to directly demonstrate that both CFTRNBD-1 and NBD-2 are
capable of binding nucleotide, and therefore provide evidence
for the presence of more than one functional CFTRnucleotide
binding site. In addition, binding affinity appears to be different
between the two domains. NBD-2 exhibits a modest (ninefold)
increase in maximal TNP-ATP fluorescence when compared
with NBD-1 (compare Figs. 2 A and 3 A), and an approximate
10-fold increase in photolabeling with 32p-2 azido ATP when
NBD-2 and NBD-1 are compared in the same experiment (data
not shown). Increased affinity of NBD-2 for a nucleotide analog
could support the notion that two NBDsof CFTRmay not have
identical roles in the maintenance of CFTRC1- channel activity.
The possibility of different functions of the two CFTRNBDs
has been suggested previously based upon studies of the influ-
ence of NBD-1 and NBD-2 mutations on the CFT`R C1- channel
in isolated membrane patches, where functional differences in
the domains led to speculation that ATP hydrolysis by CFTR
was dependent primarily on NBD-2 rather than NBD-1 (5).
Although a high resolution crystal structure is not yet avail-
able for any of the ABC protein NBDs, Chou-Fasman based
predicted secondary structure of the CFTR and other NBDs
corresponds very closely to that of non-ABC, known nucleotide
binding proteins such as adenylate kinase, p21 ras, and the
elongation factor, Tu. The striking alignment of the predicted
2° structure of the CFTR NBD and the known structure of
these other proteins has been used to predict the functional
consequences of disease-associated CFTRmutations. For exam-
ple, a model of the CFTRNBDbased on 20 structural homology
with adenylate kinase (12) predicted that the AF508 mutation
would be spatially so distant from the nucleotide binding pocket
of CFTR NBD-1 that it would not disrupt ATP binding. Our
results are consistent with this prediction. No specific prediction
was made concerning the G -+ D mutations at CFTRpositions
551 and 1349. In an attempt to relate NBD tertiary structural
models to our findings concerning nucleotide binding, assign-
ment of the corresponding locations of these residues within
the known adenylate kinase tertiary structure was performed.
As shown in Fig. 4, assignment of the positions of G551
and G1349 is straightforward based on previously determined
alignments (12). These residues would be predicted to fall
immediately after the third /8 strand in both the adenylate kinase
and the predicted CFTR NBD structure. In addition, in the
original CFTRNBDmodel, the ATP binding pocket was as-
signed to a large cleft corresponding to the AMPbinding site
in adenylate kinase. When this binding site is appropriately
adjusted based on the most recent crystallographic and NMR
data available for the location of the AMPbinding site in ade-
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Figure 4. Positions of residues
G551 and G1349 in a tertiary
structural model of the NBD
based on adenylate kinase. The
similarities between predicted sec-
ondary structure of ABCprotein
NBDs and the known structure of
adenylate kinase, together with the
structural similarities of nucleo-
tide binding sites within diverse,
unrelated proteins outside of the
ABC family (e.g., between ade-
nylate kinase, the elongation fac-
tor Tu and p21 ras), suggest that
the tertiary structure of nucleotide
binding sites in the NBDs of
CFI7R and other ABCfamily
members may closely resemble
those of adenylate kinase (12, 13,
35). In an attempt to relate previ-
ous tertiary structural models of
CFTRto our findings of defective
nucleotide binding by the G551D
and G1349D NBDs, we predicted
the location of these residues
based on previous alignments of
CFTRNBDs with adenylate ki-
nase. As shown in the Figure,
G551 and G1349 occur in a loop
immediately following the third /s
strand of both the adenylate kinase
and the CFTRNBDmodels (49,
50; the prediction also conforms
to the CFTRNBDmodel of ref.
12). The Walker A sequence is
part of a connecting loop between
the first /3 strand and an a helix.
Both the Walker A motif and the
residues at G551 or G1349 are
predicted to fall within a large
cleft suitable for nucleotide bind-
ing; this cleft is known both by
NMRand x-ray crystallography to
bind AMPwithin the adenylate ki-
nase molecule. The two views
above are - 900 rotated from each
other; the /3 strands are green, a
helices are blue, and the loops are
white. The Walker A site and the
location of G551 or G1349 are
shown in red. A ball and stick
model of AMPis shown in a nu-
cleotide binding site. The atoms
are colored according to the fol-
lowing code: N, blue, 0, red, C,
green, P. yellow. The figure was
prepared using the program Rib-
bon 2.0 (51).
nylate kinase (49, 50), as shown in Fig. 4, G551 and G1349
are on the wall of a cleft suitable for ATP binding within the
NBD. Another wall of the cleft is formed by the so-called p-
loop or Walker A motif (GXXXXGKT/S) which is (a) present
in nearly all ATP binding proteins, (b) known to contain resi-
dues which actually coordinate with phosphate groups of ATP
(such as the p-loop lysine within p21 ras), and (c) highly likely
to be involved in ATP binding by the CFTRand other NBDs,
since the conservation of this motif is invariant through the
ABCgene family (1, 12, 35, 36). Recent data from our labora-
tories has also shown that a peptide containing residues 1335
to 1351 is covalently labeled in the intact NBD-2 by 32p-2-
azido ATP, suggesting the proximity of this region to the ATP
binding site within the NBD. Thus our findings of diminished
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nucleotide binding mediated by G551D and G1349D, as well
as normal binding by LF508, provide experimental evidence
supporting predictions of the structure of the ATP binding site
within the CFTRNBD. The results further support the notion
that the LSGGQXQRmotif found within all ABC proteins is
involved in normal nucleotide binding, and in fact may form a
critical portion of an ATP binding cleft. An essential role in
nucleotide binding could explain the high level of conservation
of this region within the ABCgene family, and would offer a
molecular mechanism by which G551Dand G1349D contribute
to clinical CF.
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